Post-earnings recap
Reported
Mon, May 11, 2026
EPS actual
$-0.60
EPS est.
$-0.19
EPS surprise
-220.86%
1-day move
+3.16%
Erasca, Inc. reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock reacted positively, increasing by 3.16%. This could indicate that investors are optimistic about future prospects or other factors not reflected in the earnings figures.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.60 | N/A | -220.86% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Erasca, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. With a market cap of $3 billion, it operates in the health care sector, which is increasingly important as advancements in medical science continue to evolve.
Last quarter
In the last quarter, Erasca reported an EPS of -$0.10, slightly beating expectations. However, the stock reacted negatively, dropping 5.48% the following day.
Management promises and guidance
EPS beat streak
0Q
EPS beat rate
63%
Avg EPS surprise
-23.28%
Avg 1-day reaction
+1.03%
Investors are cautiously optimistic about Erasca's upcoming earnings report, especially given its recent performance. However, uncertainty remains due to the lack of analyst estimates.
Bull case
If Erasca can demonstrate significant progress in its clinical trials and report better-than-expected EPS, it could lead to a positive stock reaction.
Bear case
On the other hand, if the company fails to show meaningful advancements or reports a larger loss than anticipated, it could lead to further declines in stock price.
The print will turn on these.
Q1
What specific updates can management provide on the progress of ongoing clinical trials?
Investors will closely watch for any advancements, as these could significantly influence the company's future prospects.
Q2
How does Erasca plan to manage costs moving forward given the current financial landscape?
Cost management is critical for biotech companies, especially in a challenging market, and could impact profitability.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±4.6%
Why consensus could be wrong
The consensus may underestimate the potential impact of recent clinical trial advancements, which could lead to better-than-expected results.
Supporting evidence
The company's recent trial updates suggest a more favorable outcome than analysts anticipate.
Options pricing indicates a significant move, suggesting that the market is bracing for potential surprises.
Key risk
If clinical trial results exceed expectations, it could shift the narrative significantly.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around the company's ability to advance its clinical programs while managing costs effectively.
Bull confirmed if
Positive updates on clinical trials leading to a projected EPS improvement of at least 10% compared to the previous quarter.
Bear confirmed if
A larger-than-expected EPS loss or negative updates on clinical trials.
What the market is pricing for the move.
Implied Move
±10.45%
Historical Avg
±4.4%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±10.6% while ERAS has averaged ±4.4% over the last 8 prints — setup is pricing rich.
ATM IV
1.2%
30d HV
213.2%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 6 of 16 (38%)
This setup has occurred 30 times across Health Care in the last 2 years. 10 of 16 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.4%, with a raw directional average of +0.3% (modestly positive historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Erasca beats expectations, history suggests a modest positive reaction, with an average 1-day move of +1.65% when they beat.
In line / cautious
An in-line report may lead to a muted response, as investors digest management's commentary on future plans.
Miss
If the company misses expectations, history suggests a potential decline of around +6.28% on the following day.
The lines on the call that would change the story.